It's difficult to assess, because there is no evidence. Basically, the challenge around off-label use is that the drug use is not supported by the same thorough evaluation. You are right, yes, that there is a risk of adverse events for off-label use, as there is for approved use. It would be very difficult to assess if there were more.
On May 1st, 2008. See this statement in context.